(Reuters) – Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
